Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Baxter | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Baxter

Revenues up 3% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Baxter
 
2Q Revenues: $3.7 billion (+3%)

2Q Earnings: $590 million (-11%)

YTD Revenues: $7.1 billion (+2%)

YTD Earnings: $1.1 billion (-9%)

Comments: BioScience revenues were $1.6 billion in the quarter (+5%), driven by hemophilia therapies ADVATE and FEIBA, as well as specialty plasma-based therapeutics and vaccines. Medical Products sales were $2.0 billion (+1%). Second quarter results include after-tax special items totaling $49 million, primarily for costs associated the planned acquisition of Gambro AB.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters